Evidence map›Paper›PMID 21976650›Full record

ArticleJournal of virology2011

Spring-loaded model revisited: paramyxovirus fusion requires engagement of a receptor binding protein beyond initial triggering of the fusion protein.

Matteo Porotto, Ilaria Devito, Samantha G Palmer, Eric M Jurgens, Jia L Yee, Christine C Yokoyama, Antonello Pessi, Anne Moscona

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 60 citations in OpenAlex.

  1. Article
  2. Article
  3. Molecular Evolution of theMicroorganisms · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Matteo PorottoDepartments of Pediatrics and of Microbiology and Immunology, Weill Medical College of Cornell University, 515 East 71st Street, 6th Floor, Box 309, New York, NY 10021, USA.
Ilaria Devito
Samantha G Palmer
Eric M Jurgens
Jia L Yee
Christine C Yokoyama
Antonello Pessi
Anne Moscona
Cornell University · USCentro di Ricerca per la Patologia Vegetale · IT

Funding

Viral Pathogenesis and TherapeuticsU54AI057158 · NIAID · WADSWORTH CENTER · PI LEVY, DAVID E · 2003 to 2014
$100.8M
Molecular basis for paramyxovirus entryR01AI031971 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI MOSCONA, ANNE · 1998 to 2016
$6.6M
Design of peptide entry inhibitors and delivery systems to target emerging henipaR01AI076335 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI MOSCONA, ANNE · 2009 to 2010
$1.5M
Bioengineering protocells for a new class of viral vaccinesR21EB011707 · NIBIB · WEILL MEDICAL COLL OF CORNELL UNIV · PI POROTTO, MATTEO · 2011 to 2012
$465k
New fusion inhibitors for childhood respiratory viruses, designed to avoid resistR21AI090354 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI MOSCONA, ANNE · 2010 to 2011
$463k
Novel brain-penetrant fusion inhibitors for control of CNS infection.R21NS076385 · NINDS · WEILL MEDICAL COLL OF CORNELL UNIV · PI POROTTO, MATTEO · 2011 to 2012
$443k
NIAID NIH HHS R01 AI031971NIAID NIH HHS R01 AI076335NIAID NIH HHS R01AI076335NIAID NIH HHS R01AI31971NIAID NIH HHS R21 AI090354NIAID NIH HHS R21AI090354NIAID NIH HHS U54 AI057158NIAID NIH HHS U54AI057158NIBIB NIH HHS R21 EB011707NINDS NIH HHS R21 NS076385PHS HHS R21EBO11707
6 · The paper itself

Abstract

During paramyxovirus entry into a host cell, receptor engagement by a specialized binding protein triggers conformational changes in the adjacent fusion protein (F), leading to fusion between the viral and cell membranes. According to the existing paradigm of paramyxovirus membrane fusion, the initial activation of F by the receptor binding protein sets off a spring-loaded mechanism whereby the F protein progresses independently through the subsequent steps in the fusion process, ending in membrane merger. For human parainfluenza virus type 3 (HPIV3), the receptor binding protein (hemagglutinin-neuraminidase [HN]) has three functions: receptor binding, receptor cleaving, and activating F. We report that continuous receptor engagement by HN activates F to advance through the series of structural rearrangements required for fusion. In contrast to the prevailing model, the role of HN-receptor engagement in the fusion process is required beyond an initiating step, i.e., it is still required even after the insertion of the fusion peptide into the target cell membrane, enabling F to mediate membrane merger. We also report that for Nipah virus, whose receptor binding protein has no receptor-cleaving activity, the continuous stimulation of the F protein by a receptor-engaged binding protein is key for fusion. We suggest a general model for paramyxovirus fusion activation in which receptor engagement plays an active role in F activation, and the continued engagement of the receptor binding protein is essential to F protein function until the onset of membrane merger. This model has broad implications for the mechanism of paramyxovirus fusion and for strategies to prevent viral entry.

Indexed as

Virus InternalizationCell LineHN ProteinHumansModels, BiologicalNipah VirusParainfluenza Virus 3, HumanProtein BindingReceptors, VirusViral Envelope ProteinsViral Fusion ProteinsF protein, Nipah virusF protein, parainfluenza virus 3HN ProteinReceptors, VirusViral Envelope ProteinsViral Fusion Proteins

Identifiers

PMID21976650
PMCPMC3233114
OpenAlexW2138520825

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.